| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.12 | 0.5 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |